// App-Quantinova.ai

: Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Researchers

Presenter

  • Sattva S. Neelapu

Principal Investigators

  • Michael Dickinson

  • Javier Munoz

  • Matthew L. Ulrickson

  • Catherine Thieblemont

  • Olalekan O. Oluwole

  • Alex F. Herrera

  • Chaitra S. Ujjani

  • Yi Lin

  • Peter A. Riedell

  • Natasha Kekre

  • Sven De Vos

  • Christine Lui

  • Francesca Milletti

  • Jinghui Dong

  • Hairong Xu

  • Julio C. Chavez

Medical Centers

  • The Ottawa Hospital, Ottawa, Canada

  • Moffitt Cancer Center, Tampa, FL

  • Banner MD Anderson Cancer Center, Gilbert, AZ

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Hemato-Oncology, Saint Louis Hospital, Paris, France

  • Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

  • Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA

  • David Geffen School of Medicine at UCLA, Santa Monica, CA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and and the University of Melbourne, Melbourne, Australia

  • City of Hope National Medical Center, Duarte, CA

  • Mayo Clinic, Rochester, MN

Locations

  • Canada

  • United States

  • Australia

  • France

Companies

  • Kite Pharma, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • B-cell lymphoma 2

  • B-cell lymphoma 6

  • cMYC

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Axicabtagene ciloleucel

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved